T
Tempest Therapeutics, Inc. (TPST)
NCM – Real Time Price. Currency in USD
1.08
+0.03 (2.86%)
At close: Jun 26, 2026, 4:00 PM EDT
1.08
0.00 (0.00%)
After-hours: Jun 26, 2026, 7:08 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.08
+0.03 (2.86%)
At close: Jun 26, 2026, 4:00 PM EDT
1.08
0.00 (0.00%)
After-hours: Jun 26, 2026, 7:08 PM EDT
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
| Name | Position |
|---|---|
| Dr. Andrew Fang Ph.D. | Head of Business Development |
| Mr. Justin Trojanowski CPA | Corporate Controller, Treasurer & Principal Accounting Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-23 | D | |
| 2026-06-23 | 8-K | d158247d8k.htm |
| 2026-06-08 | DEF 14A | ny20072803x2_def14a.htm |
| 2026-06-04 | 8-K | d91703d8k.htm |
| 2026-06-02 | 8-K | d105562d8k.htm |
| 2026-05-29 | PRE 14A | ny20072803x1_pre14a.htm |
| 2026-05-29 | 8-K | d220128d8k.htm |
| 2026-05-22 | 8-K | d29824d8k.htm |
| 2026-05-14 | 8-K | tpst-20260514.htm |
| 2026-05-14 | 10-Q | tpst-20260331.htm |